Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer

Shameem, Raji; Hamid, Muhammad Saad; Xu, Kevin Y; Wu, Shenhong

doi:10.5306/wjco.v6.i4.64

Cited by 9 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of signaling pathways have been suggested to be involved in NSCLC progression, and have been targets of clinical and literature research. It was hypothesized that NSCLC may become resistant to therapies through feedback mechanisms that may compensate for targeted inhibition ( 55 ). Molecular targets of the VEGF and ERK/AKT pathways may simultaneously inhibit two important signaling pathways activated in NSCLC cells and may overcome one potential aspect of resistance to single-agent therapy.…”

Section: Discussionmentioning

confidence: 99%

Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways

2018

View full text Add to dashboard Cite

Non-small cell lung carcinoma (NSCLC) is the most common cause of cancer-associated mortality in the world and accounts for ~85% of human lung cancers. Metastasis-associated protein 2 (MTA2) is a component of the histone deacetylase complex and serves a role in tumor progression; however, the mechanism through which MTA2 is involved in the progression of NSCLC remains unclear. The aim of the present study was to investigate the expression and function of MTA2 and the MTA2-mediated signaling pathway in NSCLC cells. Expression of MTA2 and its target genes was analyzed in MTA2-overexpressing and anti-MTA2 antibody (AbMTA2)-treated NSCLC cells, as well as growth, migration, invasion and apoptotic-resistance. The inhibitory effects on tumor formation were analyzed using AbMTA2-treated NSCLC cells and in a mouse model. Histological assessment was conducted to analyze the expressions levels of extracellular signal-regulated kinase (ERK), RAC-α serine/threonine protein kinase (AKT) and vascular endothelial growth factor (VEGF) in experimental tumors. Results of the present study demonstrated that MTA2 was overexpressed in NSCLC cells. The growth, migration and invasion of NSCLC cells were markedly inhibited by AbMTA2. In addition, it was observed that the ERK/AKT and VEGF signaling pathways were both upregulated in MTA2-overexpressing NSCLC cells, and downregulated following silencing of MTA2 activation. ERK and AKT phosphorylation levels were downregulated in NSCLC cells and tumors following MTA2 silencing. The in vivo study demonstrated that tumor growth was markedly inhibited following siRNA-MTA2 treatment. In conclusion, the results of the present study suggested that MTA2 silencing may significantly inhibit the growth and aggressiveness of NSCLC cells. Results from the present study indicated that the mechanism underlying the MTA2-mediated invasive potential of NSCLC cells involved the ERK/AKT and VEGF signaling pathways, which may be a potential therapeutic target for the treatment of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways

2018

View full text Add to dashboard Cite

show abstract

“…Therefore, rational use of multiple drugs is of vital importance. The optimal order of drugs has also been investigated [ 33 ]. Shameem and colleagues reported that postchemotherapy may lessen the efficacy of abiraterone in patients with mCRPC.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison

Zheng

Chen

Qiu

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Recently, several drugs have been introduced for the first-line treatment of chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), but few studies have compared treatment outcomes directly. This indirect comparison among 10 clinical trials (n = 4870 patients) retrieved from PubMed, Web of Science, Cochrane Collaboration, and ClinicalTrails.gov was performed to assess the safety and efficacy of docetaxel, cabazitaxel, abiraterone, enzalutamide, and sipuleucel-T for the initial treatment of mCRPC. No significant differences in primary outcome (overall survival) were found among initial treatments. However, docetaxel had the highest probability (37.53%) of being the most effective, but at the cost of more adverse events, while enzalutamide was associated with the best secondary outcomes (prostate-specific antigen response, progression-free survival, quality of life, and adverse event profile). Thus, docetaxel is recommended as the first agent used for the chemotherapy of mCRPC, while enzalutamide is recommended as the first nonchemotherapy treatment. Additional clinical trials are needed to confirm these findings and establish the optimal order for multidrug treatment of mCRPC.

show abstract

“…The present study was conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (13). Experimental protocols were approved by the Chinese Association for Laboratory Animal Sciences (Guangzhou, China) and Animal Health Products and the Committee on the Ethics of Animal Experiments Defense Research (Guangzhou, China).…”

Section: Methodsmentioning

confidence: 99%

“…Research suggests that tumors become resistant to therapy via feedback mechanisms that compensate for targeted inhibition (13). The upregulation of hypoxia-inducible factor 1 target genes, such as VEGF, has been implicated in RCC (12).…”

Section: Introductionmentioning

confidence: 99%

Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma

Cai

Tang

Shen

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor β, RET and KIT. Cellular immunotherapy has the potential to be a highly targeted treatment, with low toxicity to normal tissues and a high capacity to eradicate tumor tissue. The present study assessed the safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lenvatinib and cellular immunotherapy in a murine model of renal cell carcinoma (RCC). The present study used a therapeutic dose of 0.12 mg lenvatinib and/or 10 4 rat uterine cancer adenocarcinoma (RuCa)-sensitized lymphocytes administered once daily continuously in 7-day cycles. Tumor regression was observed in mice with RCC following treatment with lenvatinib and 10 4 RuCa-sensitized lymphocytes. MTD was established as once daily administration of 0.18 mg lenvatinib and 10 6 RuCa-sensitized lymphocytes. The most common treatment-related adverse effects observed were fatigue (40%), mucosal inflammation (30%), proteinuria, diarrhea, vomiting, hypertension and nausea (all 40%). Combination therapy using lenvatinib and cellular immunotherapy enhanced the antitumor effect induced by single treatments and prolonged the survival of mice with RCC compared with either of the single treatments. Treatment with lenvatinib (0.12 mg) combined with 10 4

show abstract

Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer

Abstract: Prior chemotherapy may reduce the effectiveness of abiraterone in patients with metastatic CRPC.

Cited by 9 publications

References 29 publications

Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways

Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways

Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison

Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma

Contact Info

Product

Resources

About